FOXO3a governs early and late apoptotic endothelial programs during elevated glucose through mitochondrial and caspase signaling

Molecular and Cellular Endocrinology

Volumn 321, Issue 2, 2010, Pages 194-206

  Hou, Jinling ^a   Chong, Zhao Zhong ^a   Shang, Yan Chen ^a   Maiese, Kenneth ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Akt1; Cell demise; Diabetes; Endothelial

Indexed keywords

CASPASE 3; CYTOCHROME C; GLUCOSE; INTERLEUKIN 1BETA CONVERTING ENZYME; PHOSPHATIDYLSERINE; PROTEIN KINASE B; TRANSCRIPTION FACTOR FKHRL1; AKT1 PROTEIN, RAT; CASPASE; FORKHEAD TRANSCRIPTION FACTOR; FOXO3A PROTEIN, RAT; GLUCOSE BLOOD LEVEL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN CELL; CELL MEMBRANE DEPOLARIZATION; CELL SURVIVAL; CELL TRANSPORT; CONTROLLED STUDY; DIABETES MELLITUS; DNA DEGRADATION; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENETIC TRANSFECTION; GLUCOSE BLOOD LEVEL; IMPAIRED GLUCOSE TOLERANCE; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN SECRETION; PROTEIN TARGETING; RAT; SIGNAL TRANSDUCTION; ANIMAL; DNA FRAGMENTATION; DRUG EFFECTS; ENDOTHELIUM; ENZYMOLOGY; GENE SILENCING; GENETICS; HYPERGLYCEMIA; METABOLISM; MITOCHONDRION; PHOSPHORYLATION; PHYSIOLOGY; SPRAGUE DAWLEY RAT; TIME; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOOD GLUCOSE; BLOTTING, WESTERN; CASPASES; DNA FRAGMENTATION; ENDOTHELIUM; FORKHEAD TRANSCRIPTION FACTORS; GENE KNOCKDOWN TECHNIQUES; GLUCOSE; HYPERGLYCEMIA; MALE; MITOCHONDRIA; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 77951254898     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2010.02.037     Document Type: Article

References (61)

1. Abbott N.J., Hughes C.C., Revest P.A., Greenwood J. Development and characterisation of a rat brain capillary endothelial culture: towards an in vitro blood-brain barrier. J. Cell Sci. 1992, 103(Pt 1):23-37.
2. Aso Y., Suganuma R., Wakabayashi S., Hara K., Nakano T., Suetsugu M., Matsumoto S., Nakamachi T., Takebayashi K., Morita K., Inukai T. Anemia is associated with an elevated serum level of high-molecular-weight adiponectin in patients with type 2 diabetes independently of renal dysfunction. Transl. Res. 2009, 154:175-182.
3. Barthelemy C., Henderson C.E., Pettmann B. Foxo3a induces motoneuron death through the Fas pathway in cooperation with JNK. BMC Neurosci. 2004, 5:48.
4. Caporali A., Sala-Newby G.B., Meloni M., Graiani G., Pani E., Cristofaro B., Newby A.C., Madeddu P., Emanueli C. Identification of the prosurvival activity of nerve growth factor on cardiac myocytes. Cell Death Differ. 2008, 15:299-311.
5. Ceriello A., dello Russo P., Amstad P., Cerutti P. High glucose induces antioxidant enzymes in human endothelial cells in culture. Evidence linking hyperglycemia and oxidative stress. Diabetes 1996, 45:471-477.
6. Chan J.C., Malik V., Jia W., Kadowaki T., Yajnik C.S., Yoon K.H., Hu F.B. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009, 301:2129-2140.
7. Charvet C., Alberti I., Luciano F., Jacquel A., Bernard A., Auberger P., Deckert M. Proteolytic regulation of Forkhead transcription factor FOXO3a by caspase-3-like proteases. Oncogene 2003, 22:4557-4568.
8. Chong Z.Z., Kang J., Li F., Maiese K. mGluRI targets microglial activation and selectively prevents neuronal cell engulfment through akt and caspase dependent pathways. Curr. Neurovasc. Res. 2005, 2:197-211.
9. Chong Z.Z., Kang J.Q., Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation 2002, 106:2973-2979.
10. Chong Z.Z., Li F., Maiese K. Group I metabotropic receptor neuroprotection requires Akt and its substrates that govern FOXO3a, Bim, and beta-catenin during oxidative stress. Curr Neurovasc Res 2006, 3:107-117.
11. Chong Z.Z., Lin S.H., Maiese K. The NAD+ precursor nicotinamide governs neuronal survival during oxidative stress through protein kinase B coupled to FOXO3a and mitochondrial membrane potential. J. Cereb. Blood Flow Metab. 2004, 24:728-743.
12. Chong Z.Z., Maiese K. Erythropoietin involves the phosphatidylinositol 3-kinase pathway, 14-3-3 protein and FOXO3a nuclear trafficking to preserve endothelial cell integrity. Br. J. Pharmacol. 2007, 150:839-850.
13. Chong Z.Z., Maiese K. Enhanced tolerance against early and late apoptotic oxidative stress in mammalian neurons through nicotinamidase and sirtuin mediated pathways. Curr. Neurovasc. Res. 2008, 5:159-170.
14. Chong Z.Z., Shang Y.C., Maiese K. Vascular injury during elevated glucose can be mitigated by erythropoietin and Wnt signaling. Curr. Neurovasc. Res. 2007, 4:194-204.
15. Donahoe S.M., Stewart G.C., McCabe C.H., Mohanavelu S., Murphy S.A., Cannon C.P., Antman E.M. Diabetes and mortality following acute coronary syndromes. JAMA 2007, 298:765-775.
16. Erol A. Unraveling the molecular mechanisms behind the metabolic basis of sporadic Alzheimer's disease. J. Alzheimers Dis. 2009.
17. Gomez-Gutierrez J.G., Souza V., Hao H.Y., Montes de Oca-Luna R., Dong Y.B., Zhou H.S., McMasters K.M. Adenovirus-mediated gene transfer of FKHRL1 triple mutant efficiently induces apoptosis in melanoma cells. Cancer Biol. Ther. 2006, 5:875-883.
18. Gossai D., Lau-Cam C.A. The effects of taurine, taurine homologs and hypotaurine on cell and membrane antioxidative system alterations caused by type 2 diabetes in rat erythrocytes. Adv. Exp. Med. Biol. 2009, 643:359-368.
19. Guarnieri G., Zanetti M., Vinci P., Cattin M.R., Barazzoni R. Insulin resistance in chronic uremia. J. Ren. Nutr. 2009, 19:20-24.
20. Hao J., Shen W., Tian C., Liu Z., Ren J., Luo C., Long J., Sharman E., Liu J. Mitochondrial nutrients improve immune dysfunction in the type 2 diabetic Goto-Kakizaki rats. J. Cell Mol. Med. 2009, 13:701-711.
21. Huber J.D., VanGilder R.L., Houser K.A. Streptozotocin-induced diabetes progressively increases blood-brain barrier permeability in specific brain regions in rats. Am. J. Physiol. Heart Circ. Physiol. 2006, 291:H2660-H2668.
22. Jacobs K.M., Pennington J.D., Bisht K.S., Aykin-Burns N., Kim H.S., Mishra M., Sun L., Nguyen P., Ahn B.H., Leclerc J., Deng C.X., Spitz D.R., Gius D. SIRT3 interacts with the daf-16 homolog FOXO3a in the mitochondria, as well as increases FOXO3a dependent gene expression. Int. J. Biol. Sci. 2008, 4:291-299.
23. Jessel R., Haertel S., Socaciu C., Tykhonova S., Diehl H.A. Kinetics of apoptotic markers in exogeneously induced apoptosis of EL4 cells. J. Cell Mol. Med. 2002, 6:82-92.
24. Jonsson H., Allen P., Peng S.L. Inflammatory arthritis requires Foxo3a to prevent Fas ligand-induced neutrophil apoptosis. Nat. Med. 2005, 11:666-671.
25. Kang J.Q., Chong Z.Z., Maiese K. Akt1 protects against inflammatory microglial activation through maintenance of membrane asymmetry and modulation of cysteine protease activity. J. Neurosci. Res. 2003, 74:37-51.
26. Kang J.Q., Chong Z.Z., Maiese K. Critical role for Akt1 in the modulation of apoptotic phosphatidylserine exposure and microglial activation. Mol. Pharmacol. 2003, 64:557-569.
27. Kim J.R., Jung H.S., Bae S.W., Kim J.H., Park B.L., Choi Y.H., Cho H.Y., Cheong H.S., Shin H.D. Polymorphisms in FOXO gene family and association analysis with BMI. Obesity (Silver Spring) 2006, 14:188-193.
28. Kuhad A., Bishnoi M., Tiwari V., Chopra K. Suppression of NF-kappabeta signaling pathway by tocotrienol can prevent diabetes associated cognitive deficits. Pharmacol. Biochem. Behav. 2009, 92:251-259.
29. Kuningas M., Magi R., Westendorp R.G., Slagboom P.E., Remm M., van Heemst D. Haplotypes in the human Foxo1a and Foxo3a genes; impact on disease and mortality at old age. Eur. J. Hum. Genet. 2007, 15:294-301.
30. Lappas M., Lim R., Riley C., Rice G.E., Permezel M. Localisation and expression of FoxO1 proteins in human gestational tissues. Placenta 2009, 30:256-262.
31. Leuner K., Hauptmann S., Abdel-Kader R., Scherping I., Keil U., Strosznajder J.B., Eckert A., Muller W.E. Mitochondrial dysfunction: the first domino in brain aging and Alzheimer's disease?. Antioxid. Redox Signal. 2007, 9:1659-1675.
32. Li Y., Wu H., Khardori R., Song Y.H., Lu Y.W., Geng Y.J. Insulin-like growth factor-1 receptor activation prevents high glucose-induced mitochondrial dysfunction, cytochrome-c release and apoptosis. Biochem. Biophys. Res. Commun. 2009, 384:259-264.
33. Lin K., Dorman J.B., Rodan A., Kenyon C. daf-16: An HNF-3/forkhead family member that can function to double the life-span of Caenorhabditis elegans. Science 1997, 278:1319-1322.
34. Maiese K. Triple play: promoting neurovascular longevity with nicotinamide, WNT, and erythropoietin in diabetes mellitus. Biomed. Pharmacother. 2008, 62:218-232.
35. Maiese K., Chong Z., Hou J., Shang Y. The " O" Class: crafting clinical care with FoxO transcription factors. Adv. Exp. Med. Biol. 2009, 665:242-260.
36. Maiese K., Chong Z.Z., Hou J., Shang Y.C. New strategies for Alzheimer's disease and cognitive impairment. Oxid. Med. Cell Longev. 2009, 2:279-290.
37. Maiese K., Chong Z.Z., Hou J., Shang Y.C. The vitamin nicotinamide: translating nutrition into clinical care. Molecules 2009, 14:3446-3485.
38. Maiese K., Chong Z.Z., Hou J., Shang Y.C. Oxidative stress: biomarkers and novel therapeutic pathways. Exp. Gerontol. 2010, 45:217-234.
39. Maiese K., Chong Z.Z., Li F., Shang Y.C. Erythropoietin: elucidating new cellular targets that broaden therapeutic strategies. Prog. Neurobiol. 2008, 85:194-213.
40. Maiese K., Chong Z.Z., Shang Y.C. OutFOXOing disease and disability: the therapeutic potential of targeting FoxO proteins. Trends Mol. Med. 2008, 14:219-227.
41. Maiese K., Chong Z.Z., Shang Y.C., Hou J. A " FOXO" in sight: targeting Foxo proteins from conception to cancer. Med. Res. Rev. 2009, 29:395-418.
42. Maiese K., Hou J., Chong Z.Z., Shang Y.C. Erythropoietin, forkhead proteins, and oxidative injury: biomarkers and biology. ScientificWorld J. 2009, 9:1072-1104.
43. Maiese K., Li F., Chong Z.Z. New avenues of exploration for erythropoietin. JAMA 2005, 293:90-95.
44. Mallat M., Marin-Teva J.L., Cheret C. Phagocytosis in the developing CNS: more than clearing the corpses. Curr. Opin. Neurobiol. 2005, 15:101-107.
45. Mari C., Karabiyikoglu M., Goris M.L., Tait J.F., Yenari M.A., Blankenberg F.G. Detection of focal hypoxic-ischemic injury and neuronal stress in a rodent model of unilateral MCA occlusion/reperfusion using radiolabeled annexin V. Eur. J. Nucl. Med. Mol. Imaging 2004, 31:733-739.
46. Monnier L., Mas E., Ginet C., Michel F., Villon L., Cristol J.P., Colette C. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006, 295:1681-1687.
47. Nakamura T., Sakamoto K. Forkhead transcription factor FOXO subfamily is essential for reactive oxygen species-induced apoptosis. Mol. Cell Endocrinol. 2007, 281(1-2):47-55.
48. Obexer P., Geiger K., Ambros P.F., Meister B., Ausserlechner M.J. FKHRL1-mediated expression of Noxa and Bim induces apoptosis via the mitochondria in neuroblastoma cells. Cell Death Differ. 2007, 14:534-547.
49. Ogg S., Paradis S., Gottlieb S., Patterson G.I., Lee L., Tissenbaum H.A., Ruvkun G. The Fork head transcription factor DAF-16 transduces insulin-like metabolic and longevity signals in C. elegans. Nature 1997, 389:994-999.
50. Pagano G., Bargero G., Vuolo A., Bruno G. Prevalence and clinical features of known type 2 diabetes in the elderly: a population-based study. Diabet. Med. 1994, 11:475-479.
51. Rebecchi K.R., Wenke J.L., Go E.P., Desaire H. Label-free quantitation: a new glycoproteomics approach. J. Am. Soc. Mass Spectrom. 2009, 20:1048-1059.
52. Ryan E.A., Imes S., Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 2004, 27:1028-1032.
53. Shang Y.C., Chong Z.Z., Hou J., Maiese K. The forkhead transcription factor FoxO3a controls microglial inflammatory activation and eventual apoptotic injury through caspase 3. Curr. Neurovasc. Res. 2009, 6:20-31.
54. Shang Y.C., Chong Z.Z., Hou J., Maiese K. FoxO3a governs early microglial proliferation and employs mitochondrial depolarization with caspase 3, 8, and 9 cleavage during oxidant induced apoptosis. Curr. Neurovasc. Res. 2009, 6:223-238.
55. Skurk C., Maatz H., Kim H.S., Yang J., Abid M.R., Aird W.C., Walsh K. The Akt-regulated forkhead transcription factor FOXO3a controls endothelial cell viability through modulation of the caspase-8 inhibitor FLIP. J. Biol. Chem. 2004, 279:1513-1525.
56. Soares M.M., King S.W., Thorpe P.E. Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases. Nat. Med. 2008, 14:1357-1362.
57. Takahashi H., Nakamura S., Asano K., Kinouchi M., Ishida-Yamamoto A., Iizuka H. Fas antigen modulates ultraviolet B-induced apoptosis of SVHK cells: sequential activation of caspases 8, 3, and 1 in the apoptotic process. Exp. Cell Res. 1999, 249:291-298.
58. Troisi R.J., Cowie C.C., Harris M.I. Diurnal variation in fasting plasma glucose: implications for diagnosis of diabetes in patients examined in the afternoon. JAMA 2000, 284:3157-3159.
59. Xu W.L., Qiu C.X., Wahlin A., Winblad B., Fratiglioni L. Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology 2004, 63:1181-1186.
60. Yano M., Hasegawa G., Ishii M., Yamasaki M., Fukui M., Nakamura N., Yoshikawa T. Short-term exposure of high glucose concentration induces generation of reactive oxygen species in endothelial cells: implication for the oxidative stress associated with postprandial hyperglycemia. Redox Rep. 2004, 9:111-116.
61. Zhu W., Bijur G.N., Styles N.A., Li X. Regulation of FOXO3a by brain-derived neurotrophic factor in differentiated human SH-SY5Y neuroblastoma cells. Brain Res. Mol. Brain Res. 2004, 126:45-56.